Physician

Fadi S Braiteh, M.D.

According to 2025 Medicare claims, Fadi Braiteh, M.D. (NPI: 1538268438) practices medical oncology in the Las Vegas-Henderson-North Las Vegas, NV market, with the plurality of this provider's patient population coming from Clark, NV. This provider's primary affiliated billing organization is ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PC (NPI: 1598770471; TIN: 88-0350180) and primary practice location at 89169-3321.

Braiteh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 655 traditional Medicare patients, billed 198,258 HCPCS/CPT codes, and received $3,575,877 in Medicare payments. The top billing code was 78815 (Nuclear medicine study from skull base to mid-thigh with ct scan). Part D data shows 1,139 prescription claims across 165 beneficiaries totaling $3,578,851 in drug costs, led by Fruzaqla (Fruquintinib). 2019 DME data shows 22 claims. Open Payments data shows 581 records totaling $476,361. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $646,067 to $3,578,851. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	584	296,082	$3,350,052
2016	513	279,509	$3,207,396
2017	501	295,962	$3,797,286
2018	532	238,200	$3,370,142
2019	710	250,864	$3,572,364
2020	713	332,773	$4,240,356
2021	645	278,358	$4,557,116
2022	535	221,627	$3,342,365
2023	621	220,785	$3,173,222
2024	655	198,258	$3,575,877

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	143	1,262	$646,067
2016	150	1,500	$1,344,934
2017	183	1,549	$1,484,013
2018	148	1,100	$1,045,647
2019	153	1,039	$1,400,928
2020	150	1,198	$1,850,820
2021	145	1,039	$1,376,153
2022	149	1,136	$1,671,956
2023	152	1,132	$2,783,362
2024	165	1,139	$3,578,851

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	59	379	$34,205
2016	33	160	$11,708
2017	N/R	N/R	N/R
2018	N/R	60	$14,231
2019	N/R	22	$519
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78815	Nuclear medicine study from skull base to mid-thigh with ct scan	252	284	$1,360
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	228	259	$303
80053	Blood test, comprehensive group of blood chemicals	205	934	$10
36415	Insertion of needle into vein for collection of blood sample	205	949	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	209	1,016	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Fruzaqla	Fruquintinib	17	476	$409,601
Lonsurf	Trifluridine/Tipiracil Hcl	23	644	$402,000
Krazati	Adagrasib	17	510	$367,320
Erleada	Apalutamide	24	720	$340,117
Lenvima	Lenvatinib Mesylate	13	390	$281,073

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	581	$476,361	Takeda Pharmaceuticals U.S.A., Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Fadi S. Braiteh, M.D.?

Tedicare shows public-source Medicare data for Fadi S. Braiteh, M.D. (NPI 1538268438), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Fadi S. Braiteh, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Fadi S. Braiteh, M.D.?

Fadi S. Braiteh, M.D. is linked to ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PC (billing NPI 1598770471) in the available physician profile data.

Does Fadi S. Braiteh, M.D. have Open Payments data?

Fadi S. Braiteh, M.D. has 581 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.